An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early ...

An expert discusses how real-world evidence and patient-reported outcomes support luspatercept’s clinical benefits, while ...

Methods: Retrospective claims of the i3 Innovus database from 7/1/2005 to 6/30/2008 were analyzed. Subjects were commercial enrollees ≥ 18 years with cancer and chemotherapy treatment, ≥ 2 ESA claims, ...

Data Suggest a Mechanism for ESA Resistance Researchers have found evidence that could help explain why some anemic CKD patients are resistant to treatment with an erythropoiesis stimulating ...

Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating ...

Patients in the vadadustat groups were less likely to need ESA rescue therapy during the primary evaluation period, with 14.2% of patients requiring intervention vs. 27.7% in the MPG-EPO group.

Once-monthly dosing of Hematide safely boosted hemoglobin in non-dialysis anemic CKD patients. BARCELONA—A novel peptide-based erythropoiesis-stimulating agent (ESA) called Hematide safely ...